Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02845323 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
A Phase 2 study of Bladder Cancer and Urothelial Carcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT02845323 is a Phase 2 study of Bladder Cancer and Urothelial Carcinoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 15 participants, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT02845323, a Phase 2 study of Bladder Cancer and Urothelial Carcinoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study evaluates the post cystectomy CD8+ tumor response of patients receiving Nivolumab plus Urelumab versus Nivolumab alone. Half the patients will receive Nivolumab plus Urelumab, while the other half will receive Nivolumab alone.
Conditions Studied
Interventions
- DRUG Nivolumab in combination with Urelumab
- DRUG Nivolumab monotherapy
Study Locations (5)
California
- UCLA Institute of Urologic Oncology - Los Angeles
Colorado
- University of Colorado Cancer Center - Aurora
Illinois
- University of Chicago - Chicago
Maryland
- Johns Hopkins Hospital - Baltimore
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-05-16 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02845323
The ClinicalTrials.gov registry entry for NCT02845323 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,754-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab in combination with Urelumab is the first listed.
NCT02845323 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT02845323 about?
NCT02845323 is a clinical study titled "Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder". This study evaluates the post cystectomy CD8+ tumor response of patients receiving Nivolumab plus Urelumab versus Nivolumab alone. Half the patients will receive Nivolumab plus Urelumab, while the other half will receive Nivolumab alone.
What is the current status of trial NCT02845323?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-05-16. Estimated completion is 2026-12.
What conditions does trial NCT02845323 study?
This clinical trial studies the following conditions: Bladder Cancer, Urothelial Carcinoma.
What interventions are being tested in trial NCT02845323?
The interventions under investigation include: Nivolumab in combination with Urelumab (DRUG), Nivolumab monotherapy (DRUG).
Who is sponsoring clinical trial NCT02845323?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02845323 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.